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ABSTRACT 
To investigate how genotype is related to phenotype and document correlations of genotype-phenotype with response 
of topical administration of dorzolamide in siblings affected with X-linked juvenile retinoschisis (XLRS). We performed a 
retrospective study on two male siblings (four eyes) with XLRS, who were treated with topical installation of 
dorzolamide. Clinical diagnosis was supported with familial genetic analysis with bi-directional Sanger sequencing of RS1 
pathogenic variant. Optical coherence tomography (OCT), fundus fluorescein angiography (FFA), ultrasound scan (U/S) 
and electroretinogram (ERG) were used in the evaluation. Central macular thickness (CMT) and best corrected visual 
acuity (BCVA) were recorded monthly for eighteen months. We performed genetic analysis in their family for mutations 
in the gene that encodes the protein retinoschisin, responsible for retinoschisis (RS1).  It was proved that phenotype 
variability might be related to the same pathogenic variant. While there was an improvement in BCVA and OCT central 
macular thickness in the patient with the mild form of disease, the visual acuity and the OCT scans of the patient with 
severe form of disease did not improve. Intrafamilial phenotypic variability between individuals sharing identical 
pathogenic variant was documented. Both our patients had a pathogenic variant in a hemizygous state at a genomic 
location in exon 6 of the RS1 gene; Frameshift mutation that is likely to cause protein truncation was identified which is 
suggested to result in greater clinical severity. Consequently, it was found that response to dorzolamide is correlated to 
phenotypic severity. 
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INTRODUCTION
X-linked juvenile retinoschisis (XLRS) is a quite rare 
disorder with a prevalence ranging between 1:5000 to 
1:25000 [1]. It is caused by pathogenic mutations in RS1, 
a gene on Xp22.13 coding retinoschisin [2]. It represents 
the most common cause of juvenile macular 
degeneration in males and characterized by degenerated 
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vitreous and retinal separation between the nerve fiber 
and ganglion cell layer [3]. In most cases, carrier females 
have unremarkable visual function and 
electroretinography  (ERG) [4]. Both inter- and 
intrafamilial variability in phenotypic expression have 
been reported [5]. Affected males typically have stellate-
like cystic maculopathy or foveal schisis which is 
predominately inferotemporal in 50% of individuals [6]. 
Deterioration in visual acuity is typically evident in 
affected males, between the ages of five and 10 years. 
Progressive visual deterioration frequently occurs after 
the fourth decade of life, before which visual impairment 
is usually mild [7]. During the later stages, the disease 
may be complicated with vitreous hemorrhage, choroidal 
sclerosis and/or retinal detachment as a result of low 
adhesiveness. Retinal atrophy resulting in blindness may 
rarely implicate the disease. Characteristic features 
detected by ERG include predominant or selective b-
wave amplitude reduction with relative preservation of 
the a-wave amplitude in affected males [6]; however, 
recent studies have shown variability [7]. Individuals can 
have a technically normal ERG in which the b-wave is still 
present [8]. Therefore, a normal ERG cannot exclude the 
diagnosis. Optical coherence tomography (OCT) is used 
to analyze retinal structures in affected males to 
characterize forms of deeper retinal pathology [9]. The 
typical cystic stellate maculopathy of XLRS involves the 
deeper retinal layers [10]. 
Topical use of carbonic anhydrase inhibitors has been 
used to reduce intraocular pressure. It has been 
described to be effective for the treatment of cystoid 
macular edema in selected patients with retinitis 
pigmentosa [11] and various groups investigated the 
effect of topical dorzolamide for the treatment of similar 
cystic lesions at the fovea in patients with XLRS [12]. We 
here presented two Greek male siblings with molecularly 
confirmed XLRS who underwent fundus photography, 
OCT, fluoroangiography, ERG, visual field test and 
ultrasonography. Optical coherence tomography before 
and after the treatment with potent topical carbonic 
anhydrase inhibitor, dorzolamide, was used to monitor 
the disease. 
METHODS 
A 15-year-old boy (patient 1) was admitted for 
consultation to the Vitreoretinal Clinic of the General 
Hospital of Patras due to uncorrectable bilateral visual 
acuity reduction. Patient had no ocular record of 
inflammation, trauma or infection. Best corrected visual 
acuity (BCVA) in both eyes (OU) was 2/10. Ocular 
mobility and anterior segment biomicroscopy had normal 
findings. Applanation tonometry recorded 12 millimeter 
of mercury (mmHg) in both eyes. Indirect 
ophthalmoscopic fundus examination showed indicative 
radiating cystoid spaces, also established as spoke wheel-
like maculopathy and peripheral schisis with congenital 
vascular veils. Peripheral dentritiform lesions consisting 
of occluded and sheathed vessels. Findings were more 
extreme in the right eye (Fig 1 A&B). Investigation with 
ultrasonography had normal findings. Fluorescein 
angiography showed window defects, but no leakage of 
dye in the cystoids spaces in both cases (Fig 1 C&D). The 
OCT (Heidelberg Spectralis) results revealed retinal 
cleavage into two distinct planes superficially connected 
with vertical palisades separated by low reflective spaces 
most conspicuous in the foveal region in the right eye 
(OD) at first visit (Fig. OD:E, Left eye (OS):H) eight (Fig 1 
OD:F. OS:I) and eighteen months following 
commencement of treatment (Fig1 OD:G, OS:J). 
 
 
Figure 1: Patient 1. Fundus Photos Showing Stellate Maculopathy and Vitreous Veils (A, B). Fundus Fluorescein Angiography Showed Veils With no 
Macular Leaking (C, D). Optical coherence tomography Images at First Visit (OD:E, OS:H) Eight (OD:F. OS:I ) and Eighteen Months Following 
Commencement of Treatment (OD:G, OS:J). Right eye (OD); Left eye (OS) 
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Electroretinogram was recorded according to the 
International Society for Clinical Electrophysiology of 
Vision (ISCEV) protocol [8], retinal electric activity was 
reduced in both eyes with maximum response of the OD: 
102,6 microwatt (μV) /41,5 millisecond (ms) and of the 
OS: 137,5 μV/42,0 ms. Visual fields 24-2 test showed 
mean deviation -23,52 decibel (dB) and -22,66dB of the 
right and left eyes, respectively. Their family medical and 
ophthalmic history was non-contributory. Elder brother’s 
(Patient 2) ophthalmic examination showed BCVA OU: 
7/10, biomicroscopy revealed foveal stellate pattern, 
OCT examination confirmed the cystic macular changes, 
visual fields test showed a mild reduction of indices 
Mean Deviation (MD): OD-3.29, OS-3.09. Both patients 
received topically 2% dorzolamide three times daily. Both 
patients were re-evaluated every month. Repeated BCVA 
and OCT measurements showed no significant 
improvement either in visual acuity or in retinal anatomy 
in the first case. However, in the second case there was a 
significant improvement in the visual acuity in both eyes 
to 8/10. Cystic foveal lesions and central macular 
thickness were reduced, (OD from 372 micrometer [μm] 
to 316μm and OS from 360μm to 327μm), in both eyes 
(Fig 2). 
 
 
Figure 2: Patient 2. (A) Optical coherence tomography Images at First Visit (OD:A, OS:C) and Eighteen Months following Commencement of Treatment 
(OD:B, OS:D), Central macular thickness Was Significantly Reduced (OU). Right eye (OD); Left eye (OS); both eyes (OU).
Bi-directional Sanger sequencing of RS1 revealed a 
pathogenic variant (c.578_579incC;p.HisfsX263) in a 
hemizygous state (genomic location X:18660220-
18660221) in exon 6 of this gene within a stretch of six 
cytosine nucleotides (c.574-579) which represents a 
frameshift mutation likely to cause protein truncation. 
Pathogenic variants have been identified in this cytosine 
stretch in multiple families with retinoschisis, which 
represents a mutational hotspot [1]. Complex 
segregation analysis determined that a mutation was 
present in a hemizygous state in his brother and his 
healthy mother as well (Fig 3). 
The study was conducted in accordance with the ethical 
standards declared in the declaration of Helsinki and was 
approved by an institutional review board; a written 
informed consent was obtained from both patients. Data 
was collected to note Ethics Committee approval. 
DISCUSSION 
X-linked juvenile retinoschisis is characterized by 
decreasing visual acuity until the fifth or sixth decades of 
life when macular atrophy happens. Averagely, visual 
acuity is around 3/10 at age 20, gradually declining to 
1/20 by age 60, usually because of macular changes [13]. 
During the first two decades of life visual acuity is around 
3/10, gradually reducing to 1/10 by age 60, usually due to 
macular atrophy. In our report patients were under 20 
years, but patient number 2 BCVA was much higher 
(8/10) than patient number 1 (2/10) which indicates 
potential difference in visual acutity due to phenotype 
variability. Apposition of the retinal layers due to 
coalescent cysts primarily in the outer plexiform and 
adjacent nuclear layers results in retinoschisis cavity. 
Foveal schisis occurs in 98% to 100% of patients [8]; the 
inferotemporal quadrant is the principal site of lesion 
location [8]. RS1 codes for retinoschisin and is the only 
gene known to cause XLRS. Studies on gene expression 
and immunolocalization of the typical protein product 
signify that it is expressed within the photoreceptors and 
has a complex interaction within retina cells. 
Retinoschisin is most highly expressed in the inner 
segments of the photoreceptors in human eye sections 
and other mammals. It is a 224-amino acid secretory 
protein (NP_000321.1) that exists as a novel disulfide-
linked octamer [14]. Our study revealed a pathogenic 
variant (c.578_579incC; p.HisfsX263) in a hemizygous 
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state (genomic location X: 18660220-18660221) in exon 
6 of this gene within a stretch of six cytosine nucleotides 
which represents a frameshift mutation likely to cause 
protein truncation. 
 
 
Figure 3: Pedigree Showing Two Affected Male Siblings and Their Mother, Who Is a Healthy Carrier. The Corresponding Chromatograms Show the 
c.578_579insC (p.His194fsX263) Variant in Exon 6 of RS1; a gene on Xp22.13 coding retinoschisin. 
Pathogenic variants are predominantly missense and 
clustered in exons 4–6, encoding the discoidin domain, 
although splice site, insertions, deletions mutations have 
been described. It has been reported that missense 
mutations lead to disease pathology by at least one of 
the following three mechanisms [14]; interfering with 
retinoschisisin secretion, octamerisation or allowing 
secretion and octamerisation but interfere with protein 
function. In our analysis the pathogenic variant was also 
located in exon 6 of the gene whithin a stretch of six 
cytosine nucleotides (c.574-579) representing a 
frameshift mutation which interferes with protein 
function, a molecule responsible to maintain adhesion of 
the structural integrity of the photoreceptor-bipolar 
synapse. Previous studies reported [12, 13, 15] efficacy of 
topical carbonic anhydrase inhibitors for the treatment 
of stellate maculopathy in XLRS without correlating the 
response to pathogenic variant and phenotype as 
represented by layers of disease severity. Significant 
correlations of genotype-phenotype in XLRS is a subject 
under debate. Certain studies state that variants that 
putatively cause protein truncation result in higher 
clinical severity [8]. In other studies it was stated that 
variants involved in milder phenotypic abnormalities are 
often seen in patients with missense variants [16]. In our 
investigation, treatment efficacy was not unequivocal or 
independent of genotype and phenotype and that mild 
disease can also result from variants involved in higher 
clinical severity as those causing protein truncation. 
Consequently, response to dorzolamide is correlated to 
phenotypic severity. Whether this is due to residual RS1 
gene expression or unidentified parameters remains to 
be further investigated. 
CONCLUSION 
Intrafamilial phenotypic variability between individuals 
with XLRS sharing identical pathogenic variant was 
documented. Both our patients had a pathogenic variant 
in a hemizygous state at a genomic location in exon 6 of 
the RS1 gene; Frameshift mutation that is likely to cause 
protein truncation was identified which is suggested to 
result in greater clinical severity; contrary to our cases 
where both extremes of the severity spectrum were 
identified. Consequently, response to dorzolamide is 
correlated to phenotypic severity. 
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